BioSpace News Archive

Harpoon Therapeutics, Inc. today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium.

Roche announced that healthcare professionals provided three of Roche’s navify digital solutions with excellent ratings, in terms of performance and satisfaction, in an independent report by KLAS® Research, a leading healthcare IT insights company.

Hemispherian AS, a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics has been granted NOK 16 million by the Research Council of Norway.

NanOlogy LLC, a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) today announced positive initial data from the Company’s ongoing Phase 2 trials of TFF VORI and TFF TAC, along with clinical data from the ongoing TFF VORI Expanded Access Program (EAP).

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that it has received an A$8.8 million research and development tax credit from the Australian Taxation Office.

19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated interim data including up to 30 months of follow-up from 39 patients enrolled in the ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington’s disease.

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company focused on the development of Superkines, announced that its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023.

Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics.